{"title":"Craft and engineering","authors":"","doi":"10.1038/s44222-026-00505-8","DOIUrl":"10.1038/s44222-026-00505-8","url":null,"abstract":"Traditional crafts are disappearing but the knowledge they embody can help bioengineers solve key challenges in device design, fabrication and accessibility.","PeriodicalId":74248,"journal":{"name":"Nature reviews bioengineering","volume":"4 11","pages":"1055-1055"},"PeriodicalIF":42.7,"publicationDate":"2026-11-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.nature.comhttps://www.nature.com/articles/s44222-026-00505-8.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149369625","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"What closed-loop insulin delivery can — and cannot — teach us","authors":"","doi":"10.1038/s44222-026-00497-5","DOIUrl":"10.1038/s44222-026-00497-5","url":null,"abstract":"Closed-loop insulin delivery is one of the great success stories of autonomous medicine. Its legacy, however, is not a universal blueprint, but the recognition that each closed-loop system must be designed around the biology, risks and lived realities of each condition.","PeriodicalId":74248,"journal":{"name":"Nature reviews bioengineering","volume":"4 10","pages":"937-938"},"PeriodicalIF":42.7,"publicationDate":"2026-10-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.nature.comhttps://www.nature.com/articles/s44222-026-00497-5.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149133327","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Fibre-architected intelligent permeable bioelectronics","authors":"Zhizhi Wu, Yufei Zhang, Qiyao Huang, Zijian Zheng","doi":"10.1038/s44222-026-00500-z","DOIUrl":"10.1038/s44222-026-00500-z","url":null,"abstract":"Digital health-care technologies are used in medical practice for continuous monitoring, personalized diagnostics and targeted therapies. At the heart of these technologies are bioelectronics that interface biological systems with electronic platforms. However, conventional rigid and impermeable devices remain incompatible with soft, dynamic tissues, limiting long-term integration and clinical performance. Fibre-architected intelligent permeable bioelectronics, constructed from soft, porous and multiscale fibre networks, provide an emerging architectural approach to addressing these limitations. Featuring mechanical compliance, intrinsic permeability and multifunctionality (such as sensing, actuation and therapeutic delivery), these devices can operate reliably and over the long term in complex biological environments. This Review highlights key properties, smart materials and fabrication strategies of fibre-architected intelligent permeable bioelectronics. We further discuss how these bioelectronic technologies enable a range of digital health-care applications, categorized by sensing modality and clinical needs, including electrophysiology, biochemical detection, biomechanical monitoring and multimodal therapies. Furthermore, features, such as optical transparency and washability, are also discussed. Finally, we outline key challenges and translational strategies for integrating these bioelectronic systems into future personalized digital health-care ecosystems. Fibre-architected intelligent permeable bioelectronics (FIPEB) use soft, porous and multiscale fibre networks to overcome the rigidity and impermeability of conventional bioelectronics, enabling stable interfaces with dynamic biological tissues. This Review highlights how FIPEB materials, properties and scalable fabrication strategies can advance digital health care through continuous monitoring, personalized diagnosis and closed-loop therapeutic systems.","PeriodicalId":74248,"journal":{"name":"Nature reviews bioengineering","volume":"4 11","pages":"1070-1089"},"PeriodicalIF":42.7,"publicationDate":"2026-10-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149369624","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Junzhu Wang (, ), Yan Li (, ), Yiguo Hong (, ), Yule Liu (, )
{"title":"Plant immune receptor engineering","authors":"Junzhu Wang \u0000 (, ), Yan Li \u0000 (, ), Yiguo Hong \u0000 (, ), Yule Liu \u0000 (, )","doi":"10.1038/s44222-026-00499-3","DOIUrl":"10.1038/s44222-026-00499-3","url":null,"abstract":"Plant pathogens and pests pose persistent threats to global crop production and food security. Plant immune receptors, including pattern recognition receptors and nucleotide-binding leucine-rich repeat receptors, represent key targets for engineering disease resistance. Deeper understanding of their structural biology and activation mechanisms has driven the development of strategies to engineer, transfer and deploy these receptors, expanding recognition specificities and enabling broad-spectrum, durable resistance to pathogens and pests in plants. In this Review, we discuss advances in identifying, transferring and engineering plant immune receptors, with an emphasis on translational strategies that support sustainable agriculture. We further examine how tools such as CRISPR-based genome editing and AI-assisted protein design could progress this field. By integrating mechanistic insights with practical applications, we aim to engage bioengineers, plant scientists and agricultural biotechnologists in addressing the urgent need for environmentally sustainable crop production systems. This Review highlights advances for identifying, transferring and engineering plant immune receptors, then discusses translational strategies for developing durable, sustainable crop protection.","PeriodicalId":74248,"journal":{"name":"Nature reviews bioengineering","volume":"4 11","pages":"1110-1130"},"PeriodicalIF":42.7,"publicationDate":"2026-10-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149369649","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"What it takes to commercialize a bone graft","authors":"Giuseppe Perale, Gianni Pertici","doi":"10.1038/s44222-026-00503-w","DOIUrl":"10.1038/s44222-026-00503-w","url":null,"abstract":"Commercializing a bio-hybrid synthetic and xenogeneic bone graft requires integrated design that treats clinical and translational constraints as product requirements. Drawing on established components and validated concepts, we developed SmartBone as an effective composite solution. Here, we share key lessons from its commercialization, including systems engineering and the need for long-term performance evidence.","PeriodicalId":74248,"journal":{"name":"Nature reviews bioengineering","volume":"4 11","pages":"1067-1069"},"PeriodicalIF":42.7,"publicationDate":"2026-10-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149369647","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Severino Jefferson Ribeiro da Silva, Alexander A. Green, Adriana Bernal, Camila González, Lindomar Pena, Jennifer C. Molloy, Fernán Federici, Keith Pardee
{"title":"Building sustainable diagnostic ecosystems for global health","authors":"Severino Jefferson Ribeiro da Silva, Alexander A. Green, Adriana Bernal, Camila González, Lindomar Pena, Jennifer C. Molloy, Fernán Federici, Keith Pardee","doi":"10.1038/s44222-026-00498-4","DOIUrl":"10.1038/s44222-026-00498-4","url":null,"abstract":"Global access to diagnostics is constrained not only by the availability of testing technologies but also by their dependence on costly supply chains that typically originate from a small number of capital-intensive biotechnology hubs. Here, we argue that integrating decentralized diagnostics with local manufacturing and research capacity is essential to building resilient, equitable and sustainable diagnostic ecosystems.","PeriodicalId":74248,"journal":{"name":"Nature reviews bioengineering","volume":"4 11","pages":"1064-1066"},"PeriodicalIF":42.7,"publicationDate":"2026-09-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.nature.comhttps://www.nature.com/articles/s44222-026-00498-4.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149369627","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Magdalini Panagiotakopoulou, Anita Goren, Daniel Reker, Avi Schroeder, Christine Allen, Daniel A. Heller
{"title":"Artificial intelligence and machine learning in nanoparticle drug delivery systems","authors":"Magdalini Panagiotakopoulou, Anita Goren, Daniel Reker, Avi Schroeder, Christine Allen, Daniel A. Heller","doi":"10.1038/s44222-026-00495-7","DOIUrl":"10.1038/s44222-026-00495-7","url":null,"abstract":"Artificial intelligence (AI), including machine learning (ML) methods, is shifting drug development pipelines from traditional, trial-and-error discovery towards computationally guided architectures that accelerate the identification of optimal formulations. In this Review, we outline the role of ML in the discovery and preclinical phases of the development pipeline for nanomedicine, in particular, focusing on nanoparticle-based delivery systems. During the formulation design and optimization stage, ML can predict the physico-chemical properties of lipid, polymeric and self-assembling nanoparticles, screen vast virtual libraries and guide the discovery of new excipients through autonomous platforms. In preclinical evaluation, ML can predict in vitro interactions, such as cellular uptake, and functional outcomes, such as transfection and cytotoxicity. Notably, ML can also model in vivo performance by integrating nanoparticle characteristics with complex biological datasets, ranging from tumour genomics to medical imaging, to predict biodistribution, tumour targeting and therapeutic outcomes. This Review also discusses the limitations of ML-driven approaches and the ongoing efforts to address these challenges. We highlight how these advancements could transform the development pipeline and improve the translation of nanoparticle-based delivery systems for clinical use. Artificial intelligence (AI) and, in particular, machine learning (ML) are being explored in the development of nanoparticle-based drug delivery systems, from formulation design to preclinical evaluation. This Review discusses how ML can predict nanoparticle properties, identify optimal formulations, discover new excipients and forecast biological and therapeutic outcomes by integrating complex datasets.","PeriodicalId":74248,"journal":{"name":"Nature reviews bioengineering","volume":"4 11","pages":"1131-1144"},"PeriodicalIF":42.7,"publicationDate":"2026-09-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149369630","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Biomolecular condensates in cancer therapy","authors":"Bin Wang, Long Zhang, Fangfang Zhou","doi":"10.1038/s44222-026-00493-9","DOIUrl":"10.1038/s44222-026-00493-9","url":null,"abstract":"Emerging evidence suggests that liquid–liquid phase separation (LLPS) is a mechanism involved in different intracellular processes by forming biomolecular condensates. Dysregulated LLPS has been implicated in multiple hallmarks of cancer, in which it contributes to tumorigenesis and modulates key signalling pathways. In this Review, we examine current evidence linking aberrant LLPS to cancer pathogenesis and evaluate the extent to which these mechanisms could be therapeutically targeted. We highlight bioengineering strategies including D-amino-acid-based interfering peptides, post-translational modification-mimetic approaches and the development of synthetic condensates for drug delivery. By integrating mechanistic insights with translational design considerations, we outline a conceptual framework for modulating biomolecular condensates to target oncogenic drivers that have historically been considered difficult to drug. Liquid–liquid phase separation (LLPS) is emerging as a key mechanism in cancer, linking biomolecular condensates to oncogenic signalling and tumorigenesis. This Review discusses evidence for dysregulated LLPS and highlights bioengineering strategies that enable therapeutic targeting of previously undruggable cancer drivers.","PeriodicalId":74248,"journal":{"name":"Nature reviews bioengineering","volume":"4 11","pages":"1090-1109"},"PeriodicalIF":42.7,"publicationDate":"2026-09-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149369629","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Marc Raynaud, Natalia Trayanova, Roslyn B. Mannon, Fabrice André, P. Murali Doraiswamy, Alexandre Loupy
{"title":"AI-enabled clinical trials","authors":"Marc Raynaud, Natalia Trayanova, Roslyn B. Mannon, Fabrice André, P. Murali Doraiswamy, Alexandre Loupy","doi":"10.1038/s44222-026-00487-7","DOIUrl":"10.1038/s44222-026-00487-7","url":null,"abstract":"Randomized controlled trials remain the gold standard for evaluating the benefits and risks of new interventions, yet they face persistent challenges including high costs constraining sample sizes, complex eligibility criteria, recruitment difficulties, prolonged follow-up periods to capture hard end points, and the growing prevalence of poorly designed studies that create noise in literature. This Review proposes an artificial intelligence (AI)-enabled clinical trial engineering framework, applicable across medical specialties. This framework builds on four stages: assembling and harmonizing multimodal data to develop and validate tools for enabling trials; matching fit-for-purpose tools to the research question and target outcome; AI-supported trial conduct, including patient-to-trial matching, surrogate end points, externally matched comparator arms, digital twins, and automated data collection and curation; and faster, evidence-based go/no-go decisions that flag non-promising drugs early. Three overarching principles operate throughout: fit-for-purpose validation, continuous regulatory engagement and human oversight. This Review illustrates the framework through representative case studies, with the iBox surrogate in transplantation, the annualized relapse rate in multiple sclerosis, heart digital twins for ventricular tachycardia, AI-assisted histology (AIM-MASH) in hepatology and a large language model for patient-to-trial matching. It further maps the evolving regulatory landscape for AI-enabled clinical trials (EMA, FDA and the EU AI Act). Applied judiciously, AI-enabled clinical trials could shorten timelines, reduce costs and accelerate both the identification of effective therapies and the earlier elimination of futile ones. Artificial intelligence is poised to reshape clinical trials, addressing challenges in design, recruitment, monitoring and conduct. This Review outlines a framework built on deeply phenotyped cohorts, validated surrogate end points, digital twins and agentic AI systems that could shorten timelines and support the trial life cycle, highlighting opportunities to accelerate drug development while maintaining rigorous regulatory and benefit–risk assessment.","PeriodicalId":74248,"journal":{"name":"Nature reviews bioengineering","volume":"4 10","pages":"970-983"},"PeriodicalIF":42.7,"publicationDate":"2026-09-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149130657","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"How to propose a Review article","authors":"","doi":"10.1038/s44222-026-00490-y","DOIUrl":"10.1038/s44222-026-00490-y","url":null,"abstract":"At Nature Reviews Bioengineering, most of our content is commissioned. However, we also consider carefully developed proposals — but only if they follow a certain structure and approach. Here is how to pitch a Review that could capture our attention.","PeriodicalId":74248,"journal":{"name":"Nature reviews bioengineering","volume":"4 9","pages":"805-805"},"PeriodicalIF":42.7,"publicationDate":"2026-09-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.nature.comhttps://www.nature.com/articles/s44222-026-00490-y.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148910052","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}